The trade: Same molecule, two routes. Both are semaglutide: the 2.4 mg weekly injection (Wegovy), or the approved 25 mg daily pill. On treatment-policy loss the injection is about a point ahead (12% vs 11%), but the pill is the gentler of the two and skips the needle and cold chain; its price is the daily fasting routine, taken on an empty stomach with limited water and a wait before eating. A higher 50 mg pill, not approved, closes that gap, but the board scores the approved 25 mg. So this stays close to a delivery choice: the injection for the last point of loss, the pill to dodge the needle if the morning routine is one you will keep.